Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus Vaccines
Viruses · 2024
DOI: 10.3390/v16060952 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Viruses, 2024. Verfasst von Eliel Nham und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea. Hauptthemen laut MEDLINE: Enzyme-Linked Immunosorbent Assay, Respiratory Syncytial Virus Infections, Antibodies, Viral, Respiratory Syncytial Virus Vaccines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Recently, respiratory syncytial virus (RSV) vaccines based on the prefusion F (pre-F) antigen were approved in the United States. We aimed to develop an enzyme-linked immunosorbent assay (ELISA)-based protocol for the practical and large-scale evaluation of RSV vaccines. Two modified pre-F proteins (DS-Cav1 and SC-TM) were produced by genetic recombination and replication using an adenoviral vector. The protocol was established by optimizing the concentrations of the coating antigen (pre-F proteins), secondary antibodies, and blocking buffer. To validate the protocol, we examined its accuracy, precision, and specificity using serum samples from 150 participants across various age groups and the standard serum provided by the National Institute of Health. In the linear correlation analysis, coating concentrations of 5 and 2.5 μg/mL of DS-Cav1 and SC-TM showed high coefficients of determination (r > 0.90), respectively. Concentrations of secondary antibodies (alkaline phosphatase-conjugated anti-human immunoglobulin G, diluted 1:2000) and blocking reagents (5% skim milk/PBS-T) were optimized to minimize non-specific reactions. High accuracy was observed for DS-Cav1 (r = 0.90) and SC-TM (r = 0.86). Further, both antigens showed high precision (coefficient of variation < 15%). Inhibition ELISA revealed cross-reactivity of antibodies against DS-Cav1 and SC-TM, but not with the attachment (G) protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.
- Vaccine Innovation Center-KU Medicine (VIC-K), Seoul 02841, Republic of Korea.
- Korea Atomic Energy Research Institute, Jeongeup 56212, Republic of Korea.
- Department of Microbiology, Korea University College of Medicine, Seoul 02841, Republic of Korea.
ORCID-Profile: A-Yeung Jang, Woo Joo Kim, Ho Seong Seo, Joon Young Song
Förderung
- Ministry of Food and Drug Safety
Zitieren
APA
Nham, E., Jang, A. Y., Ji, H. J., Ahn, K. B., Bae, J. Y., Park, M. S., Yoon, J. G., Seong, H., Noh, J. Y., Cheong, H. J., Kim, W. J., Seo, H. S., & Song, J. Y. (2024). Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus Vaccines. Viruses. https://doi.org/10.3390/v16060952
Vancouver
Nham E, Jang AY, Ji HJ, Ahn KB, Bae JY, Park MS, et al. Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus Vaccines. Viruses. 2024. doi:10.3390/v16060952
BibTeX
@article{Nham2024,
author = {Nham, Eliel and Jang, A-Yeung and Ji, Hyun Jung and Ahn, Ki Bum and Bae, Joon-Yong and Park, Man-Seong and Yoon, Jin Gu and Seong, Hye and Noh, Ji Yun and Cheong, Hee Jin and Kim, Woo Joo and Seo, Ho Seong and Song, Joon Young},
title = {Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus Vaccines},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16060952}
}
EUVIMED